Douglas Earl Martin 4
4 · Allogene Therapeutics, Inc. · Filed Aug 17, 2023
Insider Transaction Report
Form 4
Douglas Earl Martin
SVP, General Counsel
Transactions
- Award
Common Stock
2023-08-14+326,876→ 435,834 total - Award
Stock Option (Right to Buy)
2023-08-14+960,854→ 960,854 totalExercise: $4.13Exp: 2033-08-14→ Common Stock (960,854 underlying) - Award
Common Stock
2023-08-14+108,958→ 108,958 total
Footnotes (2)
- [F1]Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028.
- [F2]25% of the shares subject to the stock option shall vest on August 14, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.